A Phase II Double-Blind Study of Two Doses of SC-49483 in Combination With Zidovudine (ZDV) Versus ZDV
Status:
Completed
Trial end date:
1995-07-01
Target enrollment:
Participant gender:
Summary
To determine the safety and anti-HIV activity of two doses of SC-49483 in combination with
zidovudine (AZT) versus AZT alone. To determine the influences of viral phenotype on the
anti-HIV activity of these treatment regimens.
SC-49483 has no inherent activity against HIV-1 but is converted in the intestinal wall to
SC-48334, which has demonstrated anti-HIV activity. Since SC-49483 causes significantly less
gastrointestinal toxicity than SC-48334, the combination of SC-49483 with AZT may improve the
benefits of both drugs in patients with HIV infection.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)